| CSF Biomarkers in Neurodegenerative Diseases | Nevin İLHAN | 8–11 |
| Proficiency Testing (PT) schemes-External Quality Assurance (EQA) programs in Molecular Tests | Alexander HALIASSOS | 11–11 |
| Urine Drug Testing: With General Aspects | Çiğdem KARAKÜKÇÜ | 12–14 |
| Drug Testing In Oral Fluid | Alain G. VERSTRAETE | 14–14 |
| Rational Laboratory Approaches in The Evaluation of Thyroid Function Testing | Dildar KONUKOĞLU | 15–16 |
| Cardiac Troponins: Current Approach From Laboratory to Clinic | Asım ÖREM,Cihan ÖREM | 21–22 |
| Laboratory of Inborn Errors of Metabolism-Test Portfolio with Examples | İncilay LAY | 23–25 |
| Hemoglobınopathies | Abdullah ARPACI,Sibel ELMACIOĞLU,Bahar ÜNLÜ | 26–26 |
| Validation and Verification Applications, Method Comparison and ROC Analysis on the Basis of CLSI Guidelines | Fatih YEŞİLDAL,Metin UYANIK,Erdim SERTOĞLU | 27–30 |
| Determination of TSH and free T4 reference ranges in pediatric age groups | Mehmet Buğrahan KALAYCI,Musa Yılmaz ACAR | 31–33 |
| Irisin and chemerin levels in patients with Type 2 diabetes mellitus | Yasemin AKGÜL BALABAN,Mehmet Buğrahan KALAYCI,Nisbet YILMAZ,Mustafa Ümit ÜNAL,Turhan TURAN | 38–40 |
| Evaluation of hsCRP, thiamine, and serotonin in fibromyalgia syndrome | Muzaffer KATAR,Köksal DEVECİ,Hülya DEVECİ | 40–41 |
| Spexin: A novel candidate biomarker for differentiating diabetic cataract and cataract disease with diabetic retinopathy | Meltem YARDIM,Ahmet Yavuz ORUÇ,Süleyman AYDIN | 43–44 |